About this item:

73 Views | 17 Downloads

Author Notes:

Correspondence: Debbie Saslow, PhD, Cancer Control Department, American Cancer Society, 250 Williams St, Suite 600, Atlanta, GA 30303; debbie.saslow@cancer.org

Debbie Saslow: Conceptualization, methodology, validation, formal analysis, investigation, resources, writing–original draft, writing–review and editing, visualization, and project administration.

Kimberly S. Andrews: Methodology, writing–original draft, writing–review and editing, and project administration.

Deana Manassaram-Baptiste: Investigation, writing–original draft, and writing–review and editing.

Lacey Loomer: Formal analysis and writing–review and editing.

Kristina E. Lam: Investigation and writing–review and editing.

Marcie Fisher-Borne: Writing–review and editing.

Robert A. Smith: Writing–review and editing, visualization, supervision, and project administration.

Elizabeth T. H. Fontham: Conceptualization, validation, writing–review and editing, and project administration.

We thank the following individuals who served as expert advisors and reviewed the recommendations, the article, and the evidence review:

L. Stewart Massad, MD (Professor, Division of Gynecologic Oncology, Washington University School of Medicine, St Louis, MO); Anna-Barbara Moscicki, MD (Professor of Pediatrics, University of California-LA, Los Angeles, CA);

Rebecca B. Perkins, MD, MS (Associate Professor of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA); Cosette M. Wheeler, PhD (Regents Professor and Director, New Mexico HPV Pap Registry, University of New Mexico Health Sciences Center, Albuquerque, NM).

Members of the American Cancer Society Guideline Development (GDG) Group: Elizabeth T. H. Fontham, MPH, DrPH, Chair (Founding Dean and Professor Emeritus, Louisiana State University School of Public Health, New Orleans, LA); Timothy R. Church, MS, PhD (Professor, Masonic Cancer Center and the University of Minnesota, Minneapolis, MN);

Ruth Etzioni, PhD (Biostatistician, University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA); Christopher R. Flowers, MD (Associate Professor, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA); Samuel J. LaMonte, MD (independent retired physician and patient advocate);

Kevin C. Oeffinger, MD (Director, Cancer Survivorship Center, Memorial Sloan Kettering Cancer Center, New York, NY); Ya-Chen Tina Shih, PhD (Professor, The University of Texas MD Anderson Cancer Center, Houston, TX);

Louise C. Walter, MD (Professor of Medicine, University of California-San Francisco and San Francisco VA Medical Center, San Francisco, CA); and Andrew M. D. Wolf, MD (Associate Professor of Medicine, University of Virginia School of Medicine, Charlottesville, VA).

Disclosures: Debbie Saslow reports being Principal Investigator of both of those cooperative agreements, and Marcie Fisher-Borne reports being co-Principal Investigator and receiving salary support through one of those cooperative agreements. All remaining authors report no conflicts of interest.


Research Funding:

The American Cancer Society (ACS) supported the development of the guideline through the use of general funds. Outside the submitted work, the ACS is the recipient of 2 cooperative agreements from the Centers for Disease Control and Prevention (CDC), Prevention and Public Health Fund, that seek to increase human papillomavirus (HPV) vaccination of girls and boys ages 11 to 12 years within the United States.


  • Advisory Committee on Immunization Practices
  • American Cancer Society
  • cancer prevention
  • guideline
  • human papillomavirus (HPV)
  • vaccine
  • American Cancer Society
  • Guidelines as Topic
  • Humans
  • Papillomavirus Infections
  • Papillomavirus Vaccines
  • United States
  • Vaccination

Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement


Journal Title:

CA: A Cancer Journal for Clinicians


Volume 66, Number 5


, Pages 375-385

Type of Work:

Article | Post-print: After Peer Review


Answer questions and earn CME/CNE. The American Cancer Society (ACS) reviewed and updated its guideline on human papillomavirus (HPV) vaccination based on a methodologic and content review of the Advisory Committee on Immunization Practices (ACIP) HPV vaccination recommendations. A literature review was performed to supplement the evidence considered by the ACIP and to address new vaccine formulations and recommendations as well as new data on population outcomes since publication of the 2007 ACS guideline. The ACS Guideline Development Group determined that the evidence supports ACS endorsement of the ACIP recommendations, with one qualifying statement related to late vaccination. The ACS recommends vaccination of all children at ages 11 and 12 years to protect against HPV infections that lead to several cancers and precancers. Late vaccination for those not vaccinated at the recommended ages should be completed as soon as possible, and individuals should be informed that vaccination may not be effective at older ages.

Copyright information:

© 2016 American Cancer Society.

Export to EndNote